Draft:Medtide
Peptide and oligonucleotide-focused contract research, development and manufacturing company
From Wikipedia, the free encyclopedia
Medtide Inc. (Chinese: 泰德医药（浙江）股份有限公司) is a peptide- and oligonucleotide-focused contract research, development and manufacturing organization (CRDMO) headquartered in Hangzhou, Zhejiang, China.[1][2] Independent industry analysis has ranked Medtide among the largest peptide-focused CRDMO providers globally, with reporting by 36Kr identifying the company as the third-largest peptide CRDMO worldwide by 2023 sales revenue.[3]
Submission declined on 20 November 2025 by Pythoncoder (talk).
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
| Submission declined on 15 November 2025 by DoubleGrazing (talk). This draft's references do not show that the subject meets Wikipedia's criteria for inclusion for organizations and companies. The draft requires multiple published secondary sources that:
Declined by DoubleGrazing 4 months ago.
| |
Comment: Primary sources and routine business reporting do not establish notability per WP:NCORP. DoubleGrazing (talk) 07:40, 15 November 2025 (UTC)
Native name | 泰德医药（浙江）股份有限公司 |
|---|---|
| Company type | Public |
| SEHK: 3880 | |
| Industry | Biotechnology |
| Headquarters | Hangzhou, Zhejiang, China |
| Products | Peptide and peptide-related active pharmaceutical ingredients |
| Services | Contract research, development and manufacturing services |
| Subsidiaries | CPC Scientific Inc. |
| Website | www |
The company provides full-cycle services from early-stage discovery and pre-clinical research to clinical development and commercial-stage production of active pharmaceutical ingredients (APIs).[1][4]
History
Medtide launched an initial public offering (IPO) on the Main Board of the Hong Kong Stock Exchange in June 2025, offering H shares under stock code 3880.HK.[5][6] The listing was underwritten by a syndicate led by Morgan Stanley Asia Limited and CITIC Securities (Hong Kong) Limited.[2] Gross proceeds from the global offering were reported at approximately HK$411 million.[5]
Financial and industry media noted that the IPO was intended to fund expansion of Medtide’s peptide production capacity and international footprint, including projects related to peptide drugs for metabolic and weight-management indications.[7][8] Coverage of the company’s trading debut described Medtide as a peptide-focused CRDMO and reported modest gains in early trading.[9]
Business
Medtide’s business model combines contract research organization (CRO) and contract development and manufacturing organization (CDMO) services for peptide-based therapeutics.[4][10] Its CRO activities focus on peptide new chemical entity (NCE) discovery and synthesis, while its CDMO services cover peptide chemistry, manufacturing and controls (CMC) development and commercial-scale manufacturing of peptide and oligonucleotide drug products.[4][10]
The company states that it primarily supplies peptide and oligonucleotide drug products rather than finished dosage forms, with customers using its APIs in the development and commercialization of peptide drugs in multiple therapeutic areas.[4] Medtide reports commercial production bases and offices in both China and the United States and provides services to pharmaceutical and biotechnology companies in more than 50 countries.[1]
Industry and financial analyses highlight Medtide’s strategic focus on the high-growth market for glucagon-like peptide-1 (GLP-1) and related peptide therapies and describe the company as one of the larger peptide- and oligonucleotide-focused CRDMO providers globally.[3][11][12]
Subsidiaries
Medtide is the parent company of CPC Scientific Inc., a contract research, development and manufacturing organization specializing in peptides and oligonucleotides. CPC Scientific is described in industry sources as a subsidiary of Medtide and as part of the group’s global CRDMO platform.[13][14]
See also
- CPC Scientific Inc.
LLM-generated pages with the below issues may be deleted without notice.
These tools are prone to specific issues that violate our policies:
Instead, only summarize in your own words a range of independent, reliable, published sources that discuss the subject.
See the advice page on large language models for more information.